NAD+ Supplements in 2025: NMN vs NR vs Liposomal vs Injectable

The Molecule at the Center of Aging Science

Every cell in the human body runs on a currency it cannot print fast enough as the decades pass. Nicotinamide adenine dinucleotide, or NAD+, is that currency: a coenzyme so fundamental to cellular energy, DNA repair, and gene expression that its decline has become one of the most scrutinized hallmarks of biological aging. By the time a person reaches their fifties, circulating NAD+ levels are roughly half what they were at twenty [1]. That single statistic has ignited a billion-dollar supplement industry, a wave of clinical trials, and a genuine scientific debate about whether restoring NAD+ can meaningfully slow human aging. The question is no longer whether NAD+ matters. The question is which NAD+ supplement form, at what dose, delivered how, actually moves the needle.

Navigating the options is harder than it sounds. Nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), liposomal NAD+, and injectable NAD+ all claim to replenish the same molecule, yet their biochemical pathways, absorption kinetics, and clinical evidence bases are strikingly different. Understanding those differences is not a matter of splitting hairs. It is the difference between a supplement that genuinely elevates intracellular NAD+ and one that raises plasma metabolites without reaching the tissues that matter most. This guide builds the full picture: from the biology of why NAD+ falls, to the head-to-head evidence on each delivery form, to the emerging science on what restored NAD+ actually does inside aging cells.

Why NAD+ Declines and Why That Decline Matters

To understand why restoring NAD+ is so compelling, it helps to understand why the body loses it in the first place. NAD+ is not consumed like a fuel that burns away. It is recycled continuously through a salvage pathway, with the enzyme nicotinamide phosphoribosyltransferase (NAMPT) serving as the rate-limiting step, converting nicotinamide back into NMN and then into NAD+. Think of NAMPT as the recycling plant and NAD+ as the bottles it processes. As humans age, the recycling plant becomes less efficient, and simultaneously more demands are placed on the supply.

Those competing demands come primarily from a family of enzymes called sirtuins and another called poly(ADP-ribose) polymerases, or PARPs. Sirtuins are often called longevity proteins because they regulate inflammation, mitochondrial biogenesis, and the epigenetic marking of DNA. PARPs are DNA repair enzymes that consume NAD+ voraciously whenever DNA damage occurs, and DNA damage accumulates with age, environmental stress, and metabolic dysfunction [2]. The more damaged the DNA, the more NAD+ PARPs burn through, leaving sirtuins starved for their cofactor. The result is a vicious cycle: aging damages DNA, DNA repair depletes NAD+, depleted NAD+ impairs sirtuins, impaired sirtuins accelerate aging.

A third class of NAD+-consuming enzymes, the CD38 ectoenzymes, adds another layer of complexity. CD38 expression increases with age and with chronic low-grade inflammation, a state researchers now call "inflammaging." CD38 is extraordinarily efficient at degrading NAD+ and is thought to be a primary driver of the age-related decline in tissue NAD+ levels [3]. Blocking CD38 with compounds like apigenin has been proposed as a complementary strategy to NAD+ precursor supplementation, though the clinical evidence for that approach remains thin.

The downstream consequences of NAD+ depletion extend across virtually every major hallmark of aging. Mitochondria, which rely on NAD+ as an electron carrier in the respiratory chain, become less efficient, generating more reactive oxygen species and less ATP per unit of substrate. Sirtuin 1 and sirtuin 3, which depend on NAD+ to deacetylate their targets, lose their grip on metabolic regulation and inflammation. Sirtuin 6, which relies on NAD+ to maintain genomic stability, pulls back from its role in DNA repair. The result is a cell that is simultaneously energy-starved, genomically unstable, and inflamed. Understanding this mechanistic landscape is essential context for evaluating what NAD+ supplements can and cannot do.

The Biosynthetic Routes: How the Body Makes NAD+

NAD+ can be synthesized from several dietary precursors, and the specific precursor a supplement uses determines the pathway it takes to reach intracellular NAD+. There are three main routes: the de novo pathway from tryptophan, the Preiss-Handler pathway from niacin (nicotinic acid), and the salvage pathway from nicotinamide, NR, and NMN.

NR enters cells directly via nucleoside transporters and is phosphorylated intracellularly by nicotinamide riboside kinases (NRKs) to form NMN, which is then adenylated to NAD+ by NMNAT enzymes. NMN, being a larger, charged molecule, was originally thought to require dephosphorylation to NR at the cell surface before entry, but research published in 2019 identified the Slc12a8 transporter as a potential direct NMN transporter in intestinal cells, bypassing that conversion step [4]. The clinical significance of this transporter in humans remains under investigation, and the debate about whether oral NMN survives gut transit intact or is largely converted to NR before absorption has not been definitively settled [5].

Nicotinic acid (niacin), the oldest known NAD+ precursor, travels through the Preiss-Handler pathway and is highly effective at raising NAD+, but causes a prostaglandin-mediated skin flushing response at therapeutic doses that limits tolerability. Nicotinamide, another niacin form, raises NAD+ through the salvage pathway but is a potent inhibitor of sirtuins at high concentrations, potentially undermining some of the downstream benefits of NAD+ restoration [6]. This pharmacological nuance is why the supplement industry has converged on NR and NMN as the preferred precursors: they raise NAD+ efficiently without the flushing of niacin or the sirtuin-inhibiting liability of nicotinamide.

The choice of NAD+ precursor is not cosmetic. Each molecule takes a different biochemical route to intracellular NAD+, with meaningfully different absorption kinetics, tissue distribution, and downstream effects.

Nicotinamide Riboside: The First Clinically Validated Precursor

NR has the longest and most robust clinical evidence base of any NAD+ precursor, partly because it was commercialized earliest and partly because it attracted serious academic investment early. The landmark 2016 study by Trammell and colleagues demonstrated that oral NR supplementation in healthy adults dose-dependently increased whole blood NAD+ and its metabolites, validating the concept of oral NAD+ precursor supplementation in humans for the first time [7]. That paper was a proof of principle, not a clinical endpoint trial, but it opened the floodgates for subsequent research.

Since then, NR has been tested in multiple human populations. A randomized, double-blind, crossover trial in healthy middle-aged and older adults found that 1,000 mg per day of NR for six weeks increased whole blood NAD+ by approximately 60% [8]. A trial in adults with mild cognitive impairment found that NR supplementation raised brain NAD+ levels as measured by phosphorus-31 magnetic resonance spectroscopy, a technically demanding measure of intracellular NAD+ in the brain [9]. This was a significant finding because demonstrating brain penetration of an orally administered supplement is notoriously difficult. However, the same study did not show statistically significant improvements in cognitive outcomes, a reminder that raising a biomarker and improving function are not the same thing.

NR has also been evaluated in the context of heart failure, Parkinson's disease, and metabolic syndrome. A pilot trial in heart failure patients showed that NR increased myocardial NAD+ levels and appeared safe, though it was powered only to assess feasibility, not clinical outcomes [10]. A small trial in Parkinson's disease patients reported that NR supplementation was associated with brain NAD+ increases and neuroprotective gene expression changes, with a phase 2 trial currently ongoing [11].

The safety profile of NR is well-established at doses up to 2,000 mg per day, with no serious adverse events reported in multiple human trials. The most commonly reported side effects are mild gastrointestinal discomfort, nausea, and fatigue at higher doses. One consideration that has attracted recent attention is the metabolism of NR to nicotinamide in the liver, and the possibility that some fraction of orally administered NR raises systemic nicotinamide to levels that could have sirtuin-inhibiting effects, though this has not been demonstrated to be a clinically meaningful problem at typical supplement doses [8].

Nicotinamide Mononucleotide: The Newer Contender

NMN sits one biosynthetic step closer to NAD+ than NR, a distinction that supplement marketers have eagerly amplified into claims of superior efficacy. The scientific picture is more nuanced. The first human pharmacokinetic study of oral NMN, published in 2020, showed that a single dose of 100, 250, or 500 mg of NMN was safe and well-tolerated and raised plasma NMN and related metabolites, but did not directly assess intracellular NAD+ in tissues [12].

Subsequent trials have been more informative. A 2022 randomized, placebo-controlled trial in healthy adults aged 65 and older found that 250 mg per day of NMN for 12 weeks significantly increased whole blood NAD+ levels and improved gait speed and grip strength, two measures of physical function that are highly predictive of longevity outcomes [13]. Another randomized trial in amateur runners found that NMN supplementation combined with exercise enhanced aerobic capacity, as measured by VO2 max, compared to exercise alone [14]. This finding is particularly interesting because VO2 max is arguably the single strongest predictor of all-cause mortality, and the intersection of NAD+ biology and exercise physiology is an active area of research.

A direct head-to-head comparison of NMN and NR in humans has not yet been published as of 2025. The preclinical data suggest broadly similar efficacy in raising tissue NAD+ levels, with some studies showing tissue-specific differences, but extrapolating these results to humans requires caution. One mouse study comparing NR and NMN found that both raised liver NAD+ equivalently, while NMN appeared more effective in certain other tissues [15]. The relevance of these tissue distribution differences to human supplementation is not yet known.

NMN has attracted some of the most prominent longevity scientists as advocates and researchers. David Sinclair of Harvard Medical School has been a public proponent of NMN supplementation based on his laboratory's research in rodents, though he has been careful to note that human trials are still needed to confirm the benefits observed in animal models. The regulatory status of NMN became complicated in late 2022 when the FDA determined that NMN could not be marketed as a dietary supplement because it was already under investigation as a new drug. That decision was later modified, but it reflects the intensity of commercial interest in this molecule and the complexity of the regulatory landscape.

NMN and NR raise NAD+ through overlapping but distinct biochemical routes. Neither has yet demonstrated clear clinical superiority over the other in a properly powered, head-to-head human trial.

Liposomal NAD+: Encapsulation as a Bioavailability Strategy

Liposomal delivery represents a different philosophy from precursor supplementation. Rather than providing a molecular building block that cells convert into NAD+, liposomal formulations encapsulate NAD+ itself inside a lipid bilayer, attempting to protect the molecule from degradation in the gut and facilitate uptake into cells. The approach borrows from pharmaceutical drug delivery, where liposomal encapsulation has been used to improve the bioavailability of drugs like doxorubicin and amphotericin B that would otherwise be rapidly degraded or poorly absorbed.

The theoretical appeal is clear. NAD+ is a large, negatively charged molecule that does not readily cross cell membranes or survive intact passage through the gut. Encapsulating it in a phospholipid bilayer, essentially building a miniature version of a cell membrane around each NAD+ molecule, should protect it from luminal enzymes and allow it to fuse with cell membranes and deliver its payload directly. In practice, the evidence is considerably thinner than the theory. Most liposomal NAD+ products on the market have not been validated in peer-reviewed pharmacokinetic studies in humans, and the quality of liposomal formulations varies enormously depending on particle size, lamellarity, and the stability of the encapsulated payload.

A handful of studies have examined liposomal delivery of NAD+ precursors, particularly NR in a liposomal form, and have shown some evidence of enhanced bioavailability compared to standard NR tablets in small cohorts, but these studies are often industry-funded and have not been independently replicated [16]. The lack of large, rigorous, independent pharmacokinetic data for liposomal NAD+ formulations makes it difficult to assess their value relative to simpler and cheaper alternatives. At typical retail prices of $60 to $120 per month, liposomal formulations command a significant premium that is not yet supported by proportionally stronger clinical evidence.

One area where liposomal delivery does show genuine promise is for molecules that have proven difficult to absorb by other routes. The fact that plain oral NAD+ is almost entirely degraded before reaching systemic circulation makes encapsulation a reasonable theoretical strategy, but the question is whether the liposomes themselves survive gastric acid long enough to matter. Enteric coating, which delays dissolution until the liposome reaches the less acidic small intestine, may improve this, but adds further formulation complexity. Consumers evaluating liposomal NAD+ products should look for third-party validated particle size data and independent bioavailability studies rather than relying on manufacturer claims alone.

Injectable NAD+: Maximum Delivery, Maximum Complexity

Intravenous and subcutaneous NAD+ administration sidesteps the entire problem of oral bioavailability by delivering the molecule directly into the bloodstream. This approach is used in clinical settings for conditions including alcohol and opioid withdrawal, where NAD+ infusion has been reported to reduce craving and withdrawal severity, though the evidence base for these applications is largely observational and the mechanistic explanation remains incomplete [17]. In recent years, IV NAD+ has migrated from addiction medicine into the longevity and wellness space, with clinics offering infusions typically ranging from 250 mg to 1,000 mg per session at costs of $200 to $1,000 per infusion.

The primary advantage of injectable NAD+ is unambiguous: it guarantees that the molecule reaches systemic circulation. A 500 mg IV infusion will deliver 500 mg of NAD+ into the bloodstream. Whether that circulating NAD+ efficiently enters cells and raises intracellular NAD+ in target tissues is a separate question. NAD+ does not readily cross cell membranes on its own; it relies on surface ectoenzymes to break it down into smaller components that can enter cells and be reassembled. This means that even intravenously delivered NAD+ may function partly as a precursor delivery system rather than direct intracellular replacement, which somewhat erodes the theoretical advantage over oral precursors.

Subcutaneous injection of NMN and NR has also been explored, with some practitioners and researchers arguing that subcutaneous delivery achieves plasma concentrations intermediate between oral and IV routes while being more practical for self-administration. Formal pharmacokinetic data for subcutaneous NAD+ precursor delivery in humans are limited, making it difficult to compare this route rigorously against oral alternatives. The practical barriers to injectable NAD+ are significant: cost, access to clinical administration, vascular access, and the not-insignificant discomfort of IV infusion, which commonly causes a flushing sensation, chest tightness, and nausea when administered too rapidly. These side effects are manageable with slow infusion rates but add complexity and monitoring requirements that make this approach unsuitable as a routine supplement strategy for most people.

Subcutaneous NMN injections are available at some longevity clinics and represent a middle ground between oral supplementation and full IV infusion. The evidence base for this specific route is still emerging, but preliminary pharmacokinetic data suggest meaningfully higher peak plasma NMN concentrations compared to oral administration, with a more favorable tolerability profile than IV NAD+. For individuals who are optimizing NAD+ as part of a comprehensive longevity protocol and who have access to clinical supervision, injectable options warrant consideration, but they should be understood as an intensification strategy rather than a first-line approach.

Comparing Bioavailability: What the Evidence Actually Shows

Bioavailability comparisons across NAD+ supplement forms are complicated by a fundamental measurement problem: the most relevant metric is intracellular NAD+ in target tissues like muscle, liver, and brain, which cannot be easily measured in living humans. Most clinical trials have used whole blood NAD+ or plasma NMN/NR as proxies, but these peripheral measures may not accurately reflect what is happening in the tissues that matter most for aging and function.

With that caveat established, the available data sketch the following picture. Oral NR at 1,000 mg raises whole blood NAD+ by approximately 50 to 100% in middle-aged to older adults, with peak plasma concentrations achieved within one to two hours and a half-life of roughly three hours [8]. Oral NMN at comparable doses appears to produce similar or slightly higher NAD+ elevations in some tissues, though the data are less consistent across studies. IV NAD+ produces an immediate and large spike in plasma NAD+ that clears over several hours, with the subsequent metabolic fate of that NAD+ in tissues not well characterized. Liposomal formulations of NR have shown in some manufacturer-sponsored studies an approximately 1.5-fold improvement in bioavailability compared to standard capsule forms, but this figure should be interpreted cautiously given the lack of independent replication.

The practical implication of these bioavailability differences may be smaller than the marketing suggests. If the intracellular NAD+ elevation achieved by a well-formulated oral NMN or NR regimen reaches a biologically saturating level for the relevant enzymes, then paying a premium for IV delivery or liposomal encapsulation provides no additional functional benefit. Conversely, for individuals with compromised gut absorption, such as those with inflammatory bowel disease or significant intestinal dysbiosis, alternative delivery routes may be genuinely warranted. This is where clinical context, rather than general supplement guidance, becomes essential.

What Restored NAD+ Actually Does: The Evidence in Human Aging

Animal studies of NAD+ precursor supplementation have produced some of the most striking findings in longevity science. NR supplementation in aged mice restored muscle, liver, and brain NAD+ levels, improved mitochondrial function, reduced senescence markers, and extended median lifespan in some models [18]. NMN supplementation in aged mice showed similar benefits plus improvements in vascular function, insulin sensitivity, and physical endurance [19]. These findings established the proof of concept for NAD+ restoration as an aging intervention and justified investment in human trials.

Human evidence is more modest and more mixed. Cardiovascular function has been one of the most studied endpoints. A randomized trial found that NR supplementation reduced arterial stiffness and systolic blood pressure in older adults with elevated blood pressure, suggesting a beneficial effect on vascular aging [20]. Skeletal muscle is another compelling target: muscle tissue expresses high levels of sirtuins and NAD+-dependent enzymes, and muscle NAD+ declines steeply with age. A 2021 trial found that NMN supplementation improved muscle insulin sensitivity and gene expression related to muscle remodeling in older women [21]. The VO2 max data from the NMN-plus-exercise trial mentioned earlier add to the picture of NAD+ precursors as potential enhancers of physical performance in aging individuals [14].

Cognitive aging is perhaps the most tantalizing target, given what is known about NAD+ and neuronal energy metabolism. Neurons are extraordinarily metabolically active and have high baseline NAD+ turnover. The brain NAD+ data from the NR trial in mild cognitive impairment are encouraging but not yet translated into demonstrated functional benefits in clinical trials [9]. A separate line of evidence concerns the relationship between NAD+ and neuroinflammation: sirtuin 1, which requires NAD+ as a cofactor, suppresses NF-kB-mediated inflammatory signaling, and its reactivation through NAD+ restoration may reduce the neuroinflammatory burden that accelerates neurodegenerative disease [6]. This mechanistic hypothesis is compelling, but the clinical evidence in human neurodegeneration remains at an early stage.

It would be a misrepresentation of the current evidence to claim that NAD+ supplementation has been proven to extend human lifespan or reverse aging. What the evidence supports is that NAD+ precursor supplementation raises tissue NAD+ levels in humans, that this elevation is associated with improvements in specific biomarkers of metabolic and vascular health, and that the safety profile at studied doses is favorable. Whether these intermediate effects translate into meaningful longevity benefits will require larger, longer trials with hard clinical endpoints. Several such trials are currently underway, including large studies of NR in heart failure, metabolic syndrome, and neurodegenerative conditions.

NAD+ and the Broader Longevity Stack: Synergies Worth Considering

NAD+ precursor supplementation does not exist in a biological vacuum. Its effects intersect with several other longevity pathways and interventions in ways that are beginning to be understood. Exercise is the most important of these intersections. Physical activity independently upregulates NAMPT, the rate-limiting enzyme in NAD+ salvage, and stimulates mitochondrial biogenesis through PGC-1 alpha, a transcriptional co-activator that is itself a downstream target of sirtuin 1 [1]. The synergy between exercise and NAD+ supplementation observed in the VO2 max trial suggests that the two may be genuinely additive rather than redundant, with supplementation amplifying an already robust physiological stimulus.

Caloric restriction and fasting also intersect with NAD+ biology in a complementary way. Fasting elevates the NAD+/NADH ratio in many tissues, activating sirtuins and other NAD+-sensitive enzymes. This is one proposed mechanism by which caloric restriction extends lifespan in model organisms, and it suggests that combining NAD+ precursor supplementation with time-restricted eating or intermittent fasting may produce additive benefits, though direct evidence for this combination in humans is limited. Metformin, the diabetes medication with well-documented effects on AMPK activation and longevity gene expression, has complex interactions with NAD+ metabolism that are still being characterized [22]. For those interested in a comprehensive metabolic longevity approach, Metformin and NAD+ precursor supplementation represent complementary rather than redundant strategies.

The AMPK pathway, which is activated by metformin, fasting, and exercise, itself promotes NAD+ synthesis by upregulating NAMPT expression, creating a network of reinforcing signals that together support cellular energy homeostasis and longevity gene activation. Understanding these intersections argues for thinking about NAD+ supplementation as one component of a coordinated longevity strategy rather than a stand-alone intervention. Healthspan's Longevity Optimization program is designed around exactly this principle: integrating evidence-based interventions that address multiple aging pathways simultaneously, with clinical oversight to personalize the approach based on individual biomarker data.

Urolithin A, produced from ellagitannins by gut bacteria, activates mitophagy, the selective autophagy of damaged mitochondria, and has been shown in human trials to improve mitochondrial efficiency in muscle. Because mitochondrial dysfunction is both a cause and a consequence of NAD+ depletion, mitophagy-promoting compounds and NAD+ precursors are increasingly being viewed as mechanistically synergistic, a hypothesis supported by preclinical data and beginning to be tested in humans. Healthspan's Mitophagy Formula addresses this pathway directly, and for individuals whose primary concern is mitochondrial aging, combining NAD+ precursor support with mitophagy activation represents a rational and evidence-informed approach.

Dosing, Timing, and Practical Considerations

Clinical trials have used a wide range of NMN and NR doses, from 100 mg per day to 2,000 mg per day, with most positive results reported at doses between 250 mg and 1,000 mg per day. The dose-response relationship for NAD+ elevation appears to be roughly linear in the lower range and to plateau at higher doses, suggesting that more is not indefinitely better. For NR, doses of 300 to 1,000 mg per day represent the range used in most successful human trials. For NMN, 250 to 500 mg per day has shown consistent effects on whole blood NAD+ and physical function measures, with some trials using higher doses without clear additional benefit.

Timing of NAD+ supplement administration relative to meals and time of day has received less rigorous study than dosing. Some practitioners recommend morning administration to align with circadian patterns of NAD+ synthesis, which peaks in the morning in humans according to circadian transcriptomic data [23]. Taking NMN or NR with a small amount of fat may improve absorption of liposomal formulations, though this is less relevant for standard capsule forms. Consistency of daily intake is more important than precise timing, as NAD+ elevation from supplementation reflects a steady-state effect rather than an acute pharmacological peak.

Product quality is a significant practical concern. The NMN and NR supplement market includes products with substantial variability in actual ingredient content compared to label claims. A 2021 independent analysis of commercially available NMN products found that multiple products contained significantly less NMN than stated, and some contained undetected impurities [24]. Consumers should prioritize products with third-party certificate of analysis verification from reputable independent laboratories, and should be skeptical of price points that are significantly below the cost of goods for high-purity pharmaceutical-grade material.

Cost is an important practical dimension that is rarely addressed honestly in the longevity supplement space. High-quality oral NMN or NR at effective doses costs approximately $60 to $150 per month from reputable suppliers. Liposomal formulations command a 50 to 100% premium over standard capsule forms. IV NAD+ infusions at clinics cost $200 to $1,000 per session and are typically recommended weekly or monthly for maintenance. Against a backdrop of clinical evidence that oral NMN and NR produce meaningful NAD+ elevation at a fraction of the cost of IV alternatives, the case for IV supplementation in otherwise healthy individuals seeking longevity optimization is not yet strongly supported by the evidence, though it may be warranted in specific clinical contexts or for individuals who prefer the certainty of confirmed delivery.

Safety, Drug Interactions, and Who Should Exercise Caution

The overall safety profile of NMN and NR is favorable based on available human data. No serious adverse events attributable to NMN or NR supplementation have been reported in published clinical trials at doses up to 2,000 mg per day. The most common reported side effects are mild: nausea, bloating, and fatigue, particularly at higher doses, and these are typically dose-dependent and resolve with dose reduction. Long-term safety data beyond twelve months are limited but currently reassuring from observational reports.

One area of ongoing scientific discussion concerns the relationship between NAD+ and cancer biology. NAD+ is required for the proliferation of cancer cells as well as normal cells, and some researchers have raised the theoretical concern that systemic NAD+ elevation could promote tumor growth. The preclinical data on this question are mixed: some studies show that NAD+ depletion can limit tumor growth, while others suggest that NAD+ repletion in normal tissues may actually reduce cancer risk by improving DNA repair and immune function [2]. There are no published human data showing that NAD+ precursor supplementation increases cancer incidence, but individuals with active cancer should discuss NAD+ supplementation with their oncologist before use.

Potential drug interactions are an underappreciated consideration. NAD+ precursors can theoretically enhance the activity of sirtuin-activating compounds and may interact with medications that affect NAD+ metabolism, including some chemotherapeutic agents that work by depleting cancer cell NAD+. Niacin, which shares biosynthetic pathways with NR and NMN, can affect lipid metabolism and interact with statins, and while NR and NMN do not appear to carry the same lipid effects at typical doses, individuals on complex medication regimens should seek medical review before starting supplementation.

Certain populations may benefit more than others from NAD+ precursor supplementation. Older adults, in whom the NAD+ deficit is largest, are the most consistently studied population and the one for which clinical benefit evidence is strongest. Individuals with metabolic dysfunction, characterized by insulin resistance, elevated inflammatory markers, or mitochondrial inefficiency, may also derive particular benefit given the centrality of NAD+ to these pathways. Athletes and physically active individuals represent another population with strong theoretical and emerging empirical rationale for NAD+ supplementation, particularly given the VO2 max data and the high metabolic demands of exercise on NAD+ turnover. For a comprehensive baseline before initiating any longevity supplement protocol, the Longevity Pro Panel provides detailed biomarker data, including metabolic and inflammatory markers, that can help clinicians and patients identify who is most likely to benefit.

The Frontier: What the Next Generation of NAD+ Research Is Asking

The NAD+ field is moving rapidly, and several questions that were unanswerable just three years ago are now being addressed in ongoing trials. One of the most important is tissue specificity: different tissues have different NAD+ dependencies and different responses to precursor supplementation. Muscle responds robustly; liver also shows strong responses; brain penetration is real but more variable. Future research is likely to reveal that optimal NAD+ supplementation strategies are tissue-specific and that different disease contexts may call for different precursors or delivery routes optimized for the relevant tissue.

The epigenetic angle is particularly compelling. NAD+-dependent sirtuins are central regulators of the epigenome, the system of chemical modifications to DNA and histones that determines which genes are expressed in which cells. Age-related epigenetic drift, the gradual loss of the precise gene expression patterns that characterize young cells, has been proposed as a unifying theory of aging by David Sinclair and others, with NAD+ depletion and sirtuin inactivation as key drivers of this drift [25]. If NAD+ restoration can partially reverse epigenetic aging, the implications would extend far beyond the metabolic and vascular benefits already documented. Early data using epigenetic clocks, algorithmic tools that estimate biological age from DNA methylation patterns, suggest that NAD+ precursor supplementation may modestly reduce biological age scores, though these findings need replication in larger, controlled trials.

Combination strategies are also being actively investigated. The synergy between NAD+ precursors and senolytics, compounds that selectively clear senescent cells, is of particular interest because senescent cells both deplete local NAD+ and release inflammatory signals that further depress NAD+ metabolism in surrounding tissues. Clearing senescent cells while simultaneously restoring NAD+ in the remaining healthy cells is a mechanistically coherent strategy that several research groups are actively pursuing. Similarly, the combination of NAD+ precursors with mTOR inhibitors like rapamycin addresses aging from complementary angles: NAD+ supports cellular energy and repair, while mTOR inhibition promotes autophagy and cellular recycling. Healthspan's Rapamycin Protocol represents a clinical embodiment of this systems-level thinking about longevity.

The long arc of NAD+ research is bending toward personalization. Baseline NAD+ levels vary significantly between individuals of the same age, influenced by genetics (particularly variants in NAMPT and CD38 genes), diet (tryptophan intake, niacin equivalents), lifestyle (exercise, alcohol consumption), and health status. This variability means that population-average supplementation recommendations may be genuinely suboptimal for many individuals. Measuring baseline and on-treatment NAD+ levels, increasingly accessible through specialized longevity labs, may soon become a standard component of personalized NAD+ supplementation protocols, allowing dose and form to be titrated to individual response rather than extrapolated from group mean data.

Conclusion: Evidence-Informed Choices in an Emerging Field

The science of NAD+ supplementation has matured considerably since the first human trials appeared less than a decade ago. What began as an extrapolation from rodent longevity studies has developed into a genuine clinical evidence base demonstrating that oral NAD+ precursors, particularly NR and NMN, meaningfully raise tissue NAD+ levels in humans and produce measurable improvements in cardiovascular, metabolic, and physical function markers. That evidence base does not yet include the long-term, hard-endpoint trials that would establish NAD+ supplementation as a proven lifespan-extending intervention, and intellectual honesty requires acknowledging that gap.

What the evidence does support is that NAD+ precursor supplementation is safe, biochemically rational, and capable of addressing a documented age-related deficit with plausible downstream benefits for the hallmarks of aging. Between NMN and NR, the choice should be guided by available evidence, product quality, and cost rather than by marketing claims of superiority that outpace the data. Liposomal formulations represent a theoretically attractive but empirically undersubstantiated premium, and injectable NAD+ is best reserved for clinical contexts where oral routes are inadequate or where the certainty of systemic delivery justifies the cost and complexity. The most important variable is not which form of NAD+ supplement a person takes, but whether they are taking it as part of a coherent, monitored longevity strategy that addresses the full complexity of biological aging, not as a single molecule expected to do the work of an entire program.